Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252220 · ClinicalTrials.gov registry record · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
A Phase 1 study of Obesity, sponsored by NeuroBo Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 139
- Enrollment target
- 1
- Study location
NCT06252220 is a Phase 1 study of Obesity that is actively recruiting participants, run by NeuroBo Pharmaceuticals. The registered enrollment target is 139 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06252220, a Phase 1 study of Obesity, is actively recruiting participants, sponsored by NeuroBo Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 139 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
Conditions Studied
Interventions
- DRUG DA-1726
- DRUG Placebo to DA-1726
Study Locations (1)
Florida
- Clinical Pharmacology of Miami, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2026-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06252220
The ClinicalTrials.gov registry entry for NCT06252220 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The listed sponsor is NeuroBo Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which DA-1726 is the first listed.
NCT06252220 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06252220 about?
NCT06252220 is a clinical study titled "First in Human Study in Subjects With Obesity, But Otherwise Healthy". This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
What is the current status of trial NCT06252220?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 139 participants. The study started on 2024-03-25. Estimated completion is 2026-11-09.
What conditions does trial NCT06252220 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06252220?
The interventions under investigation include: DA-1726 (DRUG), Placebo to DA-1726 (DRUG).
Who is sponsoring clinical trial NCT06252220?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252220 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.